ArticleCureus2026
Posterior Reversible Encephalopathy Syndrome Associated With Severe Proton Pump Inhibitor-Induced Hypomagnesemia: A Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a potentially reversible cause of acute neurological deterioration. Hypertension is the most common trigger, but metabolic and drug-related causes must also be considered. We describe a patient who developed PRES with posterior circulation involvement in the absence of hypertension. The patient showed severe hypomagnesemia after prolonged proton pump inhibitor (PPI) use, where the onset of neurological symptoms occurred after the increase of esomeprazole (40 mg/day). Brain magnetic resonance imaging (MRI) showed PRES findings in the cerebellum, evolving into a gliotic lesion. Hypomagnesemia may promote endothelial dysfunction and vasogenic edema and has been increasingly linked to PRES. In patients with PRES and no clear trigger, serum magnesium should be monitored, especially in long-term PPI users. This case highlights a reversible and preventable cause of PRES, supporting the need to monitor serum magnesium and prescribe PPIs with caution in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.